J. Felgueiras

Dialysate bicarbonate variation in maintenance hemodiafiltration patients: Impact on serum bicarbonate, intradialytic hypotension and interdialytic weight gain

J. Clemente, Márcio Viegas, C. Cândido, 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

Angiotensin-converting enzyme inhibitors after renal transplantation.

P. Ponce, P. Bravo, C. Oliveira, 2008, Transplantation proceedings.

"Isolated" granulomatous interstitial nephritis and renal failure: an unusual presentation of sarcoidosis

J. Vinhas, A. Farinha, J. Assunção, 2012 .

Deletion of the 5′exons of COL4A6 is not needed for the development of diffuse leiomyomatosis in patients with Alport syndrome

J. Oliveira, A. D. de Brouwer, M. Brito, 2013, Journal of Medical Genetics.

Conversion from calcineurin inhibitors to sirolimus in renal transplant patients

P. Ponce, P. Bravo, C. Oliveira, 2008 .

Alagille Syndrome: An ultrafiltration dilemma

P. Domingues, J. Assunção, Á. Vaz, 2021, Portuguese Journal of Nephrology & Hypertension.

Renal Transplantation in Patients With Positive Lymphocytotoxicity Crossmatches: One Center’s Experience

C. Magee, S. Tullius, K. Tinckam, 2008, Transplantation.

Haemolytic uraemic syndrome associated with H1N1 influenza

J. Vinhas, A. Farinha, J. Assunção, 2010, NDT plus.

Risk of technique failure and death in fungal peritonitis is determined mainly by duration on peritoneal dialysis: single-center experience of 24 years.

R. Selgas, Sara Romero, O. Celadilla, 2006, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

Amanita poisonings resulting in acute, reversible renal failure: new cases, new toxic Amanita mushrooms.

M. Kirchmair, Fernanda Carvalho, I. Melo, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Reversible posterior leukoencephalopathy syndrome in a renal transplant patient

O. Gutiérrez, S. Tullius, K. Tinckam, 2008 .

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.